MedPath
HSA Approval

SITAGLIPTIN-METFORMIN SANDOZ FILM COATED TABLET 50MG/850MG

SIN17120P

SITAGLIPTIN-METFORMIN SANDOZ FILM COATED TABLET 50MG/850MG

SITAGLIPTIN-METFORMIN SANDOZ FILM COATED TABLET 50MG/850MG

October 24, 2024

NOVARTIS (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

A10BD07

Manufacturer Information

NOVARTIS (SINGAPORE) PTE LTD

Sandoz Private Limited

Active Ingredients

Metformin hydrochloride

850mg

Metformin

Sitagliptin phosphate Monohydrate eqv Sitagliptin

50mg

Sitagliptin

Documents

Package Inserts

SITAGLIPTIN-METFORMIN SANDOZ FILM COATED TABLET PI.pdf

Approved: October 24, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SITAGLIPTIN-METFORMIN SANDOZ FILM COATED TABLET 50MG/850MG - HSA Approval | MedPath